Cargando…
Iodine contrast agents do not influence Platelet-Rich Plasma function at an early time point in vitro
BACKGROUND: Iodine contrast agents (ICAs) are routinely used by radiologists to help guide intra-articular infiltrations. The aim of this study was to assess the in vitro effects of ICA on platelet function of human autologous Platelet-Rich Plasma (PRP). METHODS: One hundred thirty-seven consecutive...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206314/ https://www.ncbi.nlm.nih.gov/pubmed/30374787 http://dx.doi.org/10.1186/s40634-018-0162-4 |
_version_ | 1783366349369638912 |
---|---|
author | Dallaudiere, B. Crombé, A. Gadeau, A. P. Pesquer, L. Peuchant, A. James, C. Silvestre, A. |
author_facet | Dallaudiere, B. Crombé, A. Gadeau, A. P. Pesquer, L. Peuchant, A. James, C. Silvestre, A. |
author_sort | Dallaudiere, B. |
collection | PubMed |
description | BACKGROUND: Iodine contrast agents (ICAs) are routinely used by radiologists to help guide intra-articular infiltrations. The aim of this study was to assess the in vitro effects of ICA on platelet function of human autologous Platelet-Rich Plasma (PRP). METHODS: One hundred thirty-seven consecutive patients with symptomatic femoral-patellar osteoarthritis were included. All were addressed to our institution for a fluoroscopy-guided intra-articular PRP infiltration of the pathological femoral-patellar joint. For each patient, 500 μl of PRP were sampled before intra-articular injection. First, PRP samples were mixed with 50 μl of 2 widely used ICA: Visipaque270® (Iodixanol, n = 58) and Iopamiron200® (Iopamidol, n = 69). PRP concentration ([PRP]) was measured at different delays of incubation (t = 0, 5, 10, 15, 20 and 30 min) enabling to calculate PRP ratio (defined as [PRP](t)/[PRP](0mn)) at each delay, for each mixture, in order to quantitatively assess the influence of ICA on PRP ratio. Second, the PRP samples of 10 additional patients were mixed with Visipaque270®, Visipaque270®, Iopamiron200® and phosphate buffer saline (PBS: control solution) in order to qualitatively assess the influence of ICA on platelet aggregation, using ADP, Collagen, Arachidonic acid and TRAP tests. The surface expression of human P-selectin, a marker of α-granule release, in the PRP + Visipaque270® and PRP + Iopamiron200® mixtures was finally compared. Repeated-measures ANOVA, classical 2-way ANOVA and Wilcoxon matched-pairs test were used to study the influence of ICA on PRP quality. RESULTS: There was no significant change in PRP ratio during the first 30mn of incubation (p = 0.991) whatever the ICA (p = 0.926). Whatever the aggregation test, there was no significant difference in the percentage of platelet aggregation between PRP + PBS, PRP + Visipaque270® and PRP + Iopamiron200® (p = 0.998), nor between PRP + PBS and PRP + Visipaque320® (p = 0.470). Finally, there was no significant difference in P-selectin expression between the PRP + Visipaque270® and PRP + Iopamiron200® mixtures (p = 0.500). CONCLUSION: At early delays of incubation, Visipaque® and Iopamiron®, which are two widely used ICA for intra-articular infiltrations, did not influence the in vitro platelet function nor the quality of PRP. |
format | Online Article Text |
id | pubmed-6206314 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-62063142018-11-09 Iodine contrast agents do not influence Platelet-Rich Plasma function at an early time point in vitro Dallaudiere, B. Crombé, A. Gadeau, A. P. Pesquer, L. Peuchant, A. James, C. Silvestre, A. J Exp Orthop Research BACKGROUND: Iodine contrast agents (ICAs) are routinely used by radiologists to help guide intra-articular infiltrations. The aim of this study was to assess the in vitro effects of ICA on platelet function of human autologous Platelet-Rich Plasma (PRP). METHODS: One hundred thirty-seven consecutive patients with symptomatic femoral-patellar osteoarthritis were included. All were addressed to our institution for a fluoroscopy-guided intra-articular PRP infiltration of the pathological femoral-patellar joint. For each patient, 500 μl of PRP were sampled before intra-articular injection. First, PRP samples were mixed with 50 μl of 2 widely used ICA: Visipaque270® (Iodixanol, n = 58) and Iopamiron200® (Iopamidol, n = 69). PRP concentration ([PRP]) was measured at different delays of incubation (t = 0, 5, 10, 15, 20 and 30 min) enabling to calculate PRP ratio (defined as [PRP](t)/[PRP](0mn)) at each delay, for each mixture, in order to quantitatively assess the influence of ICA on PRP ratio. Second, the PRP samples of 10 additional patients were mixed with Visipaque270®, Visipaque270®, Iopamiron200® and phosphate buffer saline (PBS: control solution) in order to qualitatively assess the influence of ICA on platelet aggregation, using ADP, Collagen, Arachidonic acid and TRAP tests. The surface expression of human P-selectin, a marker of α-granule release, in the PRP + Visipaque270® and PRP + Iopamiron200® mixtures was finally compared. Repeated-measures ANOVA, classical 2-way ANOVA and Wilcoxon matched-pairs test were used to study the influence of ICA on PRP quality. RESULTS: There was no significant change in PRP ratio during the first 30mn of incubation (p = 0.991) whatever the ICA (p = 0.926). Whatever the aggregation test, there was no significant difference in the percentage of platelet aggregation between PRP + PBS, PRP + Visipaque270® and PRP + Iopamiron200® (p = 0.998), nor between PRP + PBS and PRP + Visipaque320® (p = 0.470). Finally, there was no significant difference in P-selectin expression between the PRP + Visipaque270® and PRP + Iopamiron200® mixtures (p = 0.500). CONCLUSION: At early delays of incubation, Visipaque® and Iopamiron®, which are two widely used ICA for intra-articular infiltrations, did not influence the in vitro platelet function nor the quality of PRP. Springer Berlin Heidelberg 2018-10-29 /pmc/articles/PMC6206314/ /pubmed/30374787 http://dx.doi.org/10.1186/s40634-018-0162-4 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Research Dallaudiere, B. Crombé, A. Gadeau, A. P. Pesquer, L. Peuchant, A. James, C. Silvestre, A. Iodine contrast agents do not influence Platelet-Rich Plasma function at an early time point in vitro |
title | Iodine contrast agents do not influence Platelet-Rich Plasma function at an early time point in vitro |
title_full | Iodine contrast agents do not influence Platelet-Rich Plasma function at an early time point in vitro |
title_fullStr | Iodine contrast agents do not influence Platelet-Rich Plasma function at an early time point in vitro |
title_full_unstemmed | Iodine contrast agents do not influence Platelet-Rich Plasma function at an early time point in vitro |
title_short | Iodine contrast agents do not influence Platelet-Rich Plasma function at an early time point in vitro |
title_sort | iodine contrast agents do not influence platelet-rich plasma function at an early time point in vitro |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206314/ https://www.ncbi.nlm.nih.gov/pubmed/30374787 http://dx.doi.org/10.1186/s40634-018-0162-4 |
work_keys_str_mv | AT dallaudiereb iodinecontrastagentsdonotinfluenceplateletrichplasmafunctionatanearlytimepointinvitro AT crombea iodinecontrastagentsdonotinfluenceplateletrichplasmafunctionatanearlytimepointinvitro AT gadeauap iodinecontrastagentsdonotinfluenceplateletrichplasmafunctionatanearlytimepointinvitro AT pesquerl iodinecontrastagentsdonotinfluenceplateletrichplasmafunctionatanearlytimepointinvitro AT peuchanta iodinecontrastagentsdonotinfluenceplateletrichplasmafunctionatanearlytimepointinvitro AT jamesc iodinecontrastagentsdonotinfluenceplateletrichplasmafunctionatanearlytimepointinvitro AT silvestrea iodinecontrastagentsdonotinfluenceplateletrichplasmafunctionatanearlytimepointinvitro |